MX2024009644A - Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. - Google Patents

Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada.

Info

Publication number
MX2024009644A
MX2024009644A MX2024009644A MX2024009644A MX2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A
Authority
MX
Mexico
Prior art keywords
subject
hba1c
weight loss
glycosylated hemoglobin
loss methods
Prior art date
Application number
MX2024009644A
Other languages
English (en)
Spanish (es)
Inventor
Diane Jorkasky
Shaharyar Khan
Francisco Portell
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Publication of MX2024009644A publication Critical patent/MX2024009644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024009644A 2022-02-07 2023-02-06 Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. MX2024009644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307470P 2022-02-07 2022-02-07
US202263382426P 2022-11-04 2022-11-04
PCT/US2023/062065 WO2023150759A1 (en) 2022-02-07 2023-02-06 Methods of weight loss in a subject with elevated hba1c

Publications (1)

Publication Number Publication Date
MX2024009644A true MX2024009644A (es) 2024-08-14

Family

ID=85569618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009644A MX2024009644A (es) 2022-02-07 2023-02-06 Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada.

Country Status (9)

Country Link
US (1) US20250134865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475842A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505632A (cg-RX-API-DMAC7.html)
KR (1) KR20240146053A (cg-RX-API-DMAC7.html)
AU (1) AU2023214495A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243643A1 (cg-RX-API-DMAC7.html)
IL (1) IL314682A (cg-RX-API-DMAC7.html)
MX (1) MX2024009644A (cg-RX-API-DMAC7.html)
WO (1) WO2023150759A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
WO2022246039A1 (en) * 2021-05-20 2022-11-24 Rivus Pharmaceuticals, Inc. Methods of treating mitochondria-related disorders

Also Published As

Publication number Publication date
US20250134865A1 (en) 2025-05-01
CA3243643A1 (en) 2023-08-10
IL314682A (en) 2024-10-01
WO2023150759A1 (en) 2023-08-10
EP4475842A1 (en) 2024-12-18
KR20240146053A (ko) 2024-10-07
JP2025505632A (ja) 2025-02-28
AU2023214495A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
Ferrini et al. CB 2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma
Nakamura et al. Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer
Simon et al. Effects of intravenous sulfide during porcine aortic occlusion-induced kidney ischemia/reperfusion injury
AR074227A1 (es) Anticuerpos contra il-6 y uso de los mismos
WO1999066917A3 (en) Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid
Takagi et al. Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice
Saiman et al. Inhibition of the CXCL 12/CXCR 4 chemokine axis with AMD 3100, a CXCR 4 small molecule inhibitor, worsens murine hepatic injury
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
AR063149A1 (es) Formulaciones a base de polipeptidos estables
ATE150975T1 (de) Peripheralisierung hämatopoietischer stammzellen
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
Nakada et al. Oral administration of geranylgeranylacetone improves survival rate in a rat endotoxin shock model: administration timing and heat shock protein 70 induction
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
JOP20210298A1 (ar) طرق وتركيبات للوقاية من مرض السكري من النوع الأول
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
Zhou et al. Adrenomedullin binding protein-1 modulates vascular responsiveness to adrenomedullin in late sepsis
Rossi et al. Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
Suzuki et al. Loss of hypoxia inducible factor‐1α aggravates γδ T‐cell‐mediated inflammation during acetaminophen‐induced liver injury
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
Córdoba-Moreno et al. Consequences of the lack of IL-10 in different endotoxin effects and its relationship with glucocorticoids
IL274563B2 (en) Methods of using and compositions containing dulaglutide
Ogiso et al. Granulocyte colony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1β
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.